Track market-moving stories before they get noisy

Is It Too Late to Buy Stryker Corp (SYK) After 3.2% Rally? GF Value Says Undervalued

On October 22, 2026, Stryker Corp SYK shares rose 3.2%, reaching a current price of $307.08. This movement comes amid a 52-week range of $267.00 to $392.55, indicating a significant recovery from its recent low.

GF Value™ verdict: The stock is currently priced at $307.08, which is 27.2% below the GF Value™ estimate of $421.93.GF Score™ of 89/100 suggests a strong overall performance based on various financial metrics.Notable signal: Insiders sold $586.1 million worth of shares over the past 12 months, indicating a lack of buying enthusiasm from those close to the company.Is SYK Overvalued or Undervalued?Stryker Corp's current price of $307.08 is substantially lower than the GF Value™ estimate of $421.93, reflecting a 27.2% margin of safety for potential investors. This suggests that the stock may be undervalued, offering an opportunity for future gains if the market corrects itself. GF Value™ is GuruFocus' proprietary estimate of a stock's intrinsic value, computed using historical trading multiples, past business growth, and future performance projections. The current valuation indicates that Stryker is modestly undervalued according to the GF Valuation label, which reinforces the potential for price appreciation.

How Does SYK's Valuation Compare to Its History?MetricCurrentHistoricalP/E (TTM)31.8x41.5xForward P/E18.4xN/AThe current P/E (TTM) of 31.8x is notably below its 5-year median P/E of 41.5x, indicating that the stock is trading at a discount compared to its historical valuation. This P/E analysis aligns with the GF Value™ verdict of undervaluation, suggesting that there could be favorable pricing for potential buyers.

What Does SYK's GF Score™ Tell Us?The GF Score™ evaluates a company's financial strength, profitability, growth prospects, valuation, and momentum. Stryker's GF Score™ of 89/100 reveals strong performance across these dimensions, with particularly high marks in profitability and growth.

MetricRatingGF Score™89Financial Strength6/10Profitability10/10Growth10/10Valuation8/10Momentum2/10The scores indicate that Stryker excels in profitability and growth, reflecting a robust business model and operational efficiency. However, the lower momentum rank of 2/10 suggests that the stock may not be experiencing favorable short-term trends, which could temper expectations for immediate price appreciation.

What Are Gurus and Insiders Doing with SYK?Currently, 11 gurus hold Stryker Corp SYK, with 6 adding to their positions and 7 trimming their holdings in recent quarters. This mixed activity among institutional investors indicates a degree of caution and divergence in opinion regarding the stock's future performance.

Insider activity has been notably negative, with insiders selling $586.1 million worth of shares over the past 12 months and no reported buying. This pattern can suggest a lack of confidence from those who are closely involved with the company, potentially raising concerns for outside investors.

What This Means for InvestorsOverall, Stryker Corp appears to be undervalued based on its GF Value™ estimate, presenting a potential opportunity for investors willing to navigate the current market dynamics. However, the significant insider selling and low momentum rank indicate that caution may be warranted. For more detailed insights, visit the Stryker Corp SYK stock page, or explore the GF Value™ page for further analysis.

Frequently Asked QuestionsWhat is SYK's GF Score™?

Stryker Corp has a GF Score™ of 89/100, indicating a strong overall performance based on key financial metrics.

Is SYK overvalued or undervalued?

Stryker is currently undervalued, with a GF Value™ estimate of $421.93 compared to the current price of $307.08.

What is SYK's P/E ratio?

The P/E ratio for Stryker Corp is 31.8x, which is significantly lower than its 5-year median of 41.5x, suggesting favorable valuation conditions.

This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].

Disclosures
I/We may personally own shares in some of the companies mentioned above. However, those positions are not material to either the company or to my/our portfolios.

A dividend stock earns its place in a long-term portfolio by doing more than mailing shareholders a quarterly check. It needs a business that can fund those payments while investing sufficiently to stay “competitive.

Investors interested in stocks from the Medical - Products sector have probably already heard of Phibro Animal Health (PAHC) and Stryker (SYK). But which of these two stocks presents investors with the better value opportunity right now?

Key Takeaways Stryker gains FDA clearance for Sonopet 3, with first clinical cases set for October and a fall 2026 launch.SYK shares gained more than 2% since the Oct. 14 announcement, despite a 7.1% year-to-date decline.Sonopet 3's RISE integration and Pulse Control aim to boost surgical efficiency, precision and adoption.
Stryker (SYK - Free Report) recently received FDA 510(k) clearance for Sonopet 3, its latest ultrasonic bone and soft tissue removal platform. Developed in collaboration with surgeons, the new system is designed to enhance surgical power, precision and workflow efficiency. The first clinical cases are expected to begin in October, with a full commercial launch anticipated later this fall.

The launch marks another step in Stryker’s efforts to strengthen its neurosurgical portfolio through product innovation and surgeon-focused technologies. The new platform could support customer engagement and create revenue growth opportunities as commercialization progresses. However, near-term financial contribution will likely depend on the pace of adoption, demand from hospitals and surgical centers, and the company's ability to translate the product's performance improvements into broader market penetration.

SYK Stock Trend Following the NewsFollowing the announcement on Oct. 14, SYK stock has gained more than 2% till yesterday’s close. Year to date, shares of the company have lost 13.4% compared with the industry’s 13.4% decline and the S&P 500’s 12% rise.

Stryker’s launch of Sonopet 3 could support its long-term growth by strengthening its neurosurgical portfolio and reinforcing its focus on surgeon-driven innovation. The platform’s enhanced power, precision and workflow integration could improve its appeal to surgeons and healthcare providers, supporting customer retention and adoption across surgical settings. Over time, successful commercialization could create incremental revenue opportunities and strengthen Stryker’s competitive positioning in the neurosurgery market.

SYK currently has a market capitalization of $108.02 billion.

Image Source: Zacks Investment Research

More on the NewsSonopet 3 was developed with feedback from hundreds of surgeons, with design improvements guided by their requirements for greater power, better ergonomics and enhanced integration in demanding surgical environments. The platform incorporates RISE, or Reimagined Integrated Surgical Experience, which is designed to support a more connected surgical workflow, and Pulse Control, which gives surgeons additional control over the removal of hard and soft tissues. These features are intended to improve usability and help streamline surgical workflows across different settings. According to Stryker, the enhancements reflect its focus on incorporating customer feedback into product development and advancing its neurosurgical technologies.

Stryker expects the first clinical cases using Sonopet 3 to begin in October, ahead of a full commercial launch anticipated later in fall 2026. The upcoming rollout will be an important step in gauging the platform's initial reception among surgeons and healthcare providers. Successful adoption could strengthen Stryker's competitive position in neurosurgery and create opportunities to deepen relationships with hospitals and surgical teams.

However, the company has not disclosed specific sales targets or the expected financial contribution from Sonopet 3. Its commercial impact will therefore depend on the pace of market adoption and the extent to which the new platform translates its performance and workflow enhancements into sustained customer demand.

Industry Prospects Favoring the MarketAccording to data provided by Persistence Market Research, the global neurosurgery market size is expected to be valued at $5.9 billion in 2026 and projected to reach $8.4 billion by 2033, expanding at a CAGR of 5.1% between 2026 and 2033.

The market is driven by the rise in global burden of neurological conditions, including traumatic brain injury, stroke, brain tumors and epilepsy, combined with rapid innovation in minimally invasive neurosurgical techniques, neuro-interventional devices and stereotactic radiosurgery systems.

Other NewsIn September, SYK announced an expansion of its Foot & Ankle portfolio, launching Prophecy Surgical Planning for the Incompass Total Ankle System and introducing Hoffmann LRF smartHEX at the 2026 American Orthopedic Foot & Ankle Society Annual Meeting. The new additions are designed to advance patient-specific surgical planning, implant flexibility and connected care across ankle replacement and limb reconstruction procedures.

SYK’s Zacks Rank & Key PicksCurrently, SYK carries a Zacks Rank #3 (Hold).

Some better-ranked stocks from the broader medical space are OPKO Health (OPK - Free Report) , Globus Medical (GMED - Free Report) and Merit Medical Systems (MMSI - Free Report) .

OPKO Health, currently flaunting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted loss of 1 cent per share, which surpassed the Zacks Consensus Estimate by 87.5%. Revenues of $163.6 million beat the Zacks Consensus Estimate by 24.7%. You can see the complete list of today’s Zacks #1 Rank stocks here.

OPK has an estimated earnings growth rate of 23.3% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 95.1%.

Globus Medical, currently carrying a Zacks Rank #2 (Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%.

GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.

Merit Medical Systems, carrying a Zacks Rank #2 at present, reported second-quarter 2026 adjusted EPS of $1.19, which beat the Zacks Consensus Estimate by 23.9%. Revenues of $418.8 million surpassed the Zacks Consensus Estimate by 3.5%.

MMSI has an estimated long-term earnings growth rate of 10.4%. MMSI’s earnings surpassed estimates in the trailing four quarters, with the average surprise being 14.1%.

LOS ANGELES, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, continues its investigation on behalf of Stryker Corporation (“Stryker” or the “Company”) (NYSE: SYK) investors concerning the Company’s possible violations of the federal securities laws.

IF YOU ARE AN INVESTOR WHO LOST MONEY ON STRYKER CORPORATION (SYK), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS.

What Happened?
On July 30, 2026, Stryker reported second quarter 2026 results. Among other things, the Company reported a “supply disruption resulted in a meaningful backorder situation with lost sales in the quarter. We have addressed the issue, and back orders should reach a manageable level by the end of Q3."

On this news, shares of Stryker fell $22.34 or 6.43% to close at $325.70 per share on July 31, 2026, thereby injuring investors.

On September 8, 2026, the Company participated in the Wells Fargo Healthcare Conference, during which the Company’s CFO Preston Wells told investors the Company had “anticipated that” the manufacturing issue “would rectify itself in the third quarter.” But “[w]hat we're seeing is that is continuing into the third quarter and certainly, it will continue.”

On this news, shares of Stryker fell $26.70, or 8.8%, to close at $276.43 per share on September 8, 2026, thereby injuring investors further.

Contact Us To Participate or Learn More:
If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us.
Charles Linehan, Esq.,
Glancy Prongay Wolke & Rotter LLP,
1925 Century Park East, Suite 2100,
Los Angeles California 90067
Email: [email protected]
Telephone: 310-201-9150 (Toll-Free: 888-773-9224)
Visit our website at www.glancylaw.com.
Follow us for updates on LinkedIn, Twitter, or Facebook.

Whistleblower Notice
Persons with non-public information regarding Stryker Corporation should consider their options to aid the investigation or take advantage of the SEC Whistleblower Program. Under the program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Charles H. Linehan at 310-201-9150 or 888-773-9224 or email [email protected].

About Glancy Prongay Wolke & Rotter LLP
Glancy Prongay Wolke & Rotter LLP (“GPWR”) is a premier law firm representing investors and consumers in securities litigation and other complex class action litigation. GPWR has been consistently ranked in the Top 50 Securities Class Action Settlements by ISS Securities Class Action Services. In 2018, GPWR was ranked a top five law firm in number of securities class action settlements, and a top six law firm for total dollar size of settlements.

With four offices across the country, GPWR’s nearly 40 attorneys have won groundbreaking rulings and recovered billions of dollars for investors and consumers in securities, antitrust, consumer, and employment class actions. GPWR’s lawyers have handled cases covering a wide spectrum of corporate misconduct and relating to nearly all industries and sectors. GPWR’s past successes have been widely covered by leading news and industry publications such as The Wall Street Journal, The Financial Times, Bloomberg Businessweek, Reuters, the Associated Press, Barron’s, Investor’s Business Daily, Forbes, and Money.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact Us:
Glancy Prongay Wolke & Rotter LLP,
1925 Century Park East, Suite 2100,
Los Angeles, CA 90067
Charles Linehan
Email: [email protected]
Telephone: 310-201-9150
Toll-Free: 888-773-9224
Visit our website at: www.glancylaw.com.

, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Stryker Corp. ("Stryker" or the "Company") (NYSE: SYK). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

The investigation concerns whether Stryker and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On September 8, 2026, Stryker's CEO disclosed at the Wells Fargo Healthcare Conference that a manufacturing problem affecting inventory supply in its peripheral vascular business, which management had previously indicated was expected to resolve during the third quarter of 2026, in fact remained unresolved and was now expected to persist into the fourth quarter. 

On this news, Stryker's stock price fell $26.70 per share, or 8.81%, to close at $276.43 per share on September 8, 2026.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes. 

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980

SOURCE Pomerantz LLP

Stryker has received FDA 510(k) clearance for Sonopet® 3 , the latest evolution of its ultrasonic bone and soft tissue removal platform. Developed in collaboration with surgeons, Sonopet 3 delivers enhanced power, precision and versatility. Customers gain access to advanced technologies including RISE and Pulse Control, supporting streamlined workflows and integration across surgical settings. , /PRNewswire/ -- Stryker (NYSE: SYK), a global leader in medical technologies, announced today that Sonopet 3, its latest ultrasonic bone and soft tissue removal platform, has received 510(k) clearance from the U.S. Food and Drug Administration.

Developed with input from hundreds of surgeons, Sonopet 3 is designed to deliver enhanced power, precision and versatility in a single platform for tissue removal. Surgeon collaboration directly shaped the new platform, informing key improvements in performance, workflow efficiency and clinical priorities.

Stryker has received FDA 510(k) clearance for Sonopet® 3, the latest evolution of its ultrasonic bone and soft tissue removal platform. "At Stryker, innovation begins with listening to our customers," said Mitch Foley, vice president and general manager of Stryker's Neurosurgical business. "Every major advancement in Sonopet 3 can be attributed to surgeon feedback, and together we're elevating the standard in neurosurgery. They told us they wanted more power, improved ergonomics and enhanced integration, helping them perform with confidence in demanding surgical environments."

In addition to performance enhancements, Sonopet 3 provides access to the platform's latest technologies, including RISE, a Reimagined Integrated Surgical Experience for a connected surgical workflow, and Pulse Control, which provides an added ability to regulate the resection of hard and soft tissues. Together, these advancements help support integration across surgical workflows.

The first clinical cases using Sonopet 3 are expected to begin in October, with a full commercial launch anticipated later this fall.

About Stryker
Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Alongside our customers around the world, we impact more than 150 million patients annually. More information is available at www.stryker.com.

Media contact
Stryker
Jenny Braga
Senior Director, External Affairs
[email protected]

SOURCE Stryker

Stryker rebounded in 2Q26, with operating momentum restored after the prior quarter's cybersecurity disruption. 2Q26 sales rose 9.4% YoY to ~$6.6 billion; organic growth reached ~9%, demonstrating resilience despite earlier headwinds. Adjusted EPS increased ~18% to $3.69, and operating margin expanded 170 bps to 27.4%, reflecting improved profitability.

A 26% price drop on a stock with a near-monopoly business model and 85% recurring revenue sounds like a warning, but one investor sees it as an invitation to keep buying.

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

My Intuitive Surgical (NASDAQ:ISRG | ISRG Price Prediction) position has grown through rallies and selloffs, and a 26.81% year-to-date decline makes it easier for me to keep buying. With shares at $414.52, the business looks stronger to me than the stock price suggests.

A Razor That Hospitals Keep Feeding The model is simple. A hospital buys or leases a da Vinci robot once. After that, it buys instruments for every procedure for years. In Q2 2026, instruments and accessories brought in $1.7349 billion, up 18%. Systems revenue was $685.0 million. Recurring revenue made up 85% of the total. The da Vinci installed base grew to 11,710 systems, and each robot added becomes another long-term buyer of instruments.

Three Receipts Behind My Conviction First, growth compounds. Procedures rose about 16% in Q2, and Ion lung-biopsy procedures rose 36%. In 2025, revenue passed $10.0647 billion, up 20.51%.

Second, margins keep expanding. Non-GAAP gross margin rose to 70.0% from 67.9%, and operating income climbed 30.74%. Non-GAAP EPS of $2.80 beat the $2.50 consensus. That made five consecutive quarterly beats.

Third, the balance sheet is a strong. Intuitive holds $8.6255 billion in cash against $2.5789 billion in total liabilities. First-half free cash flow reached $1.8 billion, up 71%. Intuitive pays no dividend. It returns cash through buybacks, including $1.1 billion in Q1. For my retirement account, that means the company reinvests in its own growth.

Why My Money Skips Medtronic and Stryker Medtronic (NYSE:MDT) pays a $2.85 dividend per share and trades at a forward P/E of 15. But its operating margin is 19.3%, compared with Intuitive’s 33.6%. Stryker (NYSE:SYK) trades at a forward P/E of 16, but its quarterly revenue grew 9.4%. Intuitive grew 18.5%. I gladly pay Intuitive’s forward P/E of 33 for that gap in growth and margins.

Tariffs and Slower Procedure Growth Could Hurt The real threat is a slowdown combined with tariffs. Management expects 2026 da Vinci procedure growth of 13.5% to 15.5%, down from 18% in 2025. Intuitive makes instruments in Mexico and endoscopes in Germany, and its guidance already includes a 1.0% tariff hit. Management warned that more tariffs could weigh heavily on results. Without a tariff refund, Q2 gross margin would have been 68.7%. China is also a harder market now, with domestic robot makers competing for business.

My thesis remains intact through all of it. Management said “the underlying disease burden is unchanged”, so procedures that patients put off still have to happen. U.S. use still rose 3%. Even a 68.7% gross margin is elite.

Why the Buy Button Stays On The da Vinci 5 base is only just over 1,700 systems, so the upgrade cycle has years left to run. Analysts expect EPS to grow from $10.7795 in 2026 to $12.0912 in 2027. Over ten years, the stock has returned 419.56%. Every robot a hospital installs keeps buying instruments, and that steady demand keeps me buying the stock.

Contact [email protected] for any questions or corrections.

What happened Stryker (NYSE: SYK) said Kevin Lobo will become Executive Chair and Spencer Stiles will become CEO on January 1, 2027. The company said the move follows a planned succession process. Stiles, now President and COO, will also join Stryker's Board at that time. Lobo joined Stryker in 2011 as Group President, became CEO

SummaryStryker is upgraded to 'Strong Buy' after a significant price pullback to $275, offering compelling value relative to historical valuation.SYK demonstrates robust organic sales growth, balanced across geographies and segments, with strong demand and elevated equipment backlogs.Key growth drivers include Mako robotic-assisted procedures, ASC expansion, and Smart Care platform integration, supporting double-digit EPS growth expectations.SYK’s solid balance sheet, Dividend Aristocrat status, and resilient demand position it for mid to high-teens annual total returns.Looking for a portfolio of ideas like this one? Members of iREIT®+HOYA Capital get exclusive access to our subscriber-only portfolios. Learn More »Ignatiev/iStock via Getty Images

Growth stocks come in all shapes, sizes, and forms. While those in the AI space come front and center for most investors, there are many in the healthcare space that are seemingly being ignored by the market. Like AI, healthcare is a

23.62K Followers

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in SYK over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

I am not an investment advisor. This article is for informational purposes and does not constitute as financial advice. Readers are encouraged and expected to perform due diligence and draw their own conclusions prior to making any investment decisions.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Investors with an interest in Medical - Products stocks have likely encountered both GE HealthCare Technologies (GEHC - Free Report) and Stryker (SYK - Free Report) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out.

Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The Zacks Rank is a proven strategy that targets companies with positive earnings estimate revision trends, while our Style Scores work to grade companies based on specific traits.

GE HealthCare Technologies has a Zacks Rank of #2 (Buy), while Stryker has a Zacks Rank of #3 (Hold) right now. Investors should feel comfortable knowing that GEHC likely has seen a stronger improvement to its earnings outlook than SYK has recently. But this is just one piece of the puzzle for value investors.

Value investors are also interested in a number of tried-and-true valuation metrics that help show when a company is undervalued at its current share price levels.

Our Value category grades stocks based on a number of key metrics, including the tried-and-true P/E ratio, the P/S ratio, earnings yield, and cash flow per share, as well as a variety of other fundamentals that value investors frequently use.

GEHC currently has a forward P/E ratio of 12.97, while SYK has a forward P/E of 18.23. We also note that GEHC has a PEG ratio of 1.69. This figure is similar to the commonly-used P/E ratio, with the PEG ratio also factoring in a company's expected earnings growth rate. SYK currently has a PEG ratio of 1.73.

Another notable valuation metric for GEHC is its P/B ratio of 2.63. The P/B is a method of comparing a stock's market value to its book value, which is defined as total assets minus total liabilities. By comparison, SYK has a P/B of 4.36.

These metrics, and several others, help GEHC earn a Value grade of B, while SYK has been given a Value grade of C.

GEHC has seen stronger estimate revision activity and sports more attractive valuation metrics than SYK, so it seems like value investors will conclude that GEHC is the superior option right now.

, /PRNewswire/ -- On September 8, 2026, investors in Stryker Corporation (NYSE: SYK) saw the price of their shares fall $26.70 (-8.8%) after the company's CFO revealed that a previously-thought resolved manufacturing issue persists. The move lower wiped out over $10 billion of Stryker's market capitalization.

The developments have prompted national shareholders rights firm Hagens Berman to open an investigation into whether Stryker was sufficiently transparent about the issue and, if not, whether the company may have violated the federal securities laws.

The firm encourages Stryker investors who suffered substantial losses to submit your losses now.  Persons with knowledge who may be able to assist the investigation are invited to contact the firm's attorneys.

Visit: www.hbsslaw.com/syk
Direct Contact Email: [email protected]
Firm Telephone: 844-916-0895

Stryker Corporation (SYK) Investigation:

The investigation is focused on the propriety of Stryker's disclosures about its Inari Medical operations and growth prospects. Stryker acquired Inari in February 2025 to supplement Stryker's Peripheral Vascular reporting unit.

On July 30, 2026, Stryker reported its Q2 2026 results and said, without providing details, that it faced supply disruptions in the Peripheral Vascular unit and that the disruption resulted in "a meaningful backorder situation with lost sales in the quarter." Nonetheless, management assured investors that "[w]e have addressed the issue and backorder should reach a manageable level by the end of Q3."

During the related earnings call that day, an analyst asked for some color on the disruption and what exactly happened. CEO Kevin Lobo said, "I'm not going to get into the details of what it was, but let's just say it did cause a significant backorder specific to one plant in the Inari business," and "[t]he backorder is pretty elevated right now."

In response, the market sent the price of Stryker shares down $22.34 (-6.4%) the next day.

Then, during the September 8, 2026 Wells Fargo Healthcare Conference, CFO Preston Wells further described the manufacturing issue as "not allowing us to reach a full supply of inventory at all of our customers[]" and "quite frankly, not allowing us to go out and really win new business."

Most concerning was his revelation that, in contrast to previous assurances, the problem "is continuing into the third quarter and will certainly continue – we expect it to continue a little bit into the fourth quarter as well."

The market negatively reacted again, sending the price of Stryker shares sharply lower that day.

"We're focused on when Stryker knew its Peripheral Vascular manufacturing problem hadn't been resolved and would persist beyond Q3," said Reed Kathrein, the Hagens Berman partner leading the firm's investigation.

If you invested in Stryker and have substantial losses, or have knowledge that will assist the firm's investigation, submit your losses now »

Whistleblowers: Persons with non-public information regarding Stryker should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].

About Hagens Berman
Hagens Berman is a global plaintiffs' rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman's team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw. 

Attorney Advertising. Prior results do not guarantee a similar outcome in any future case.

Contact: Hagens Berman, Reed Kathrein, 715 Hearst Avenue, Suite 300, Berkeley, CA 94710, 844-916-0895, [email protected]

SOURCE Hagens Berman Sobol Shapiro LLP

Strong performance across the healthtech sector over the past two quarters has sparked renewed market interest in medical innovation. Given the volume of inquiries landing on our desks, we compiled this guide to answer a mix of the most frequent and most interesting questions we have received regarding our Healthcare Technology and Innovation Index (HTEC).

What Is the HTEC Index?
The ROBO Global Healthcare Technology and Innovation Index is a global benchmark tracking public companies that drive innovation across the healthcare technology value chain. It captures breakthroughs like surgical robotics, AI drug discovery, gene editing, AI-driven diagnostics, and targeted precision therapies through a proprietary framework of nine subsectors, including robotics, genomics, precision medicine, and diagnostics.

What Types of Companies Are Included in the HTEC Portfolio?
The HTEC Index includes global publicly traded companies that derive a distinct portion of their revenue and business operations from disruptive technologies in healthcare. These range from small- to large-cap market leaders operating across our nine proprietary subsectors.

Importantly, revenue alone does not determine inclusion. Every company is evaluated using a proprietary Theme Score (1–100) that factors in revenue purity, technological and market leadership, as well as R&D investment. Only companies scoring 50 or higher qualify, with the final portfolio selecting the top-ranked companies, up to a maximum of 100 constituents.

How Are the Companies in the Index Weighted? 
Unlike traditional market-cap-weighted benchmarks, HTEC weights its constituents based on their proprietary Theme Score. Each company’s weight is calculated by dividing its individual Theme Score by the total sum of Theme Scores across all index members. 

This ensures that companies demonstrating higher revenue purity, stronger technological leadership, and significant R&D investment receive a larger share of the index, rather than simply awarding the highest weights to the largest mega-cap stocks.

Is HTEC Focused on Mid- & Small-Cap, or Are Large-Cap Names Included, Too?
The overall composition of HTEC is size-agnostic. While companies must pass minimum market cap and liquidity thresholds to qualify, selection and weighting are driven by exposure to our nine proprietary subsectors and each company’s composite Theme Score.

Historically, the index has hovered around 60% large-cap, with the remainder distributed across small- and mid-cap companies. This sets HTEC apart from traditional, market-cap-weighted healthcare benchmarks, which tend to be heavily dominated by mega-cap pharmaceutical giants, insurers, and hospital conglomerates.

Our smaller constituents are typically specialized, high-growth companies pioneering single-focus technologies. This includes gene-sequencing and synthetic biology firms like Twist Bioscience (TWST) and Natera (NTRA), liquid biopsy pioneers like Guardant Health (GH), and advanced clinical AI platforms like Tempus AI (TEM). These companies represent the cutting edge of precision medicine, though they typically carry higher growth volatility.

On the other hand, our large-cap holdings are global leaders with massive healthcare technology footprints that form the backbone of industry-wide innovation. This includes major diversified life sciences giants and medical device leaders such as Thermo Fisher Scientific (TMO), Danaher (DHR), Illumina (ILMN), Moderna (MRNA), and Vertex Pharmaceuticals (VRTX).

Where Does HTEC Fit Best Within a Client’s Portfolio Strategy?
HTEC is typically used as a satellite growth allocation to gain targeted exposure to long-term innovation in healthcare. Because the index maintains minimal overlap with broad market benchmarks, it provides true thematic diversification without simply duplicating mega-cap tech or traditional healthcare holdings.

What Exactly Is Precision Medicine, & Why Is the Industry Shifting Toward It?
Think of precision medicine as custom-tailored healthcare. Historically, medicine operated on a one-size-fits-all model, giving every patient with the same condition the exact same standard treatment and relying on trial and error to see what worked. Precision medicine replaces that guesswork by leveraging genetic, molecular, and lifestyle data to pinpoint the root cause of a disease in a specific body, delivering the right therapy to the right patient at the right time.

This industry-wide shift is being driven by rapid breakthroughs in low-cost DNA sequencing, real-time health monitoring, and AI diagnostics. Instead of just managing general symptoms based on broad population averages, doctors can now target the exact genetic driver of an illness, delivering therapies that are significantly more effective while causing far fewer side effects.

Do Diagnostics & Precision Medicine Overlap, or Are They Completely Separate Types of Businesses?
Think of diagnostics and precision medicine as two sides of the same coin: One detects the problem, and the other treats it.

Diagnostics focuses on tools, next-generation imagery, and molecular testing used to detect diseases and decode a patient’s genetic profile. It provides the biological map needed to understand exactly what is happening inside the body.

Precision medicine focuses on creating custom therapies tailored to that specific biological map. Instead of relying on broad, mass-market drugs, precision medicine companies develop targeted treatments designed for an individual’s specific genetic code, lifestyle, or environment.

HTEC tracks both subsectors because a breakthrough in precision therapeutics is only as good as the diagnostic tools available to identify the right patients for it.

How Is AI Currently Used in Healthcare? 
Artificial intelligence is currently used as an intelligence multiplier across healthcare. It takes massive, complex datasets, like full-genome sequences, medical scans, and health records, and turns them into actionable clinical insights.

In practice, clinicians and researchers use AI to detect diseases like cancer much earlier, predict patient risk factors, and compress years of drug discovery research into months. By automating complex data analysis and routine clinical documentation, AI allows medical professionals to move away from trial-and-error medicine and deliver faster, more personalized care, with fewer side effects. 

What Are the Primary Challenges Facing AI Adoption in Healthcare?
Key hurdles include strict patient data privacy regulations (such as HIPAA), the need to eliminate algorithmic bias through diverse clinical datasets, integration friction with legacy hospital IT systems, and the rigorous regulatory approval processes required by agencies like the FDA.

Does the Index Have Exposure to AI Drug Discovery? 
Yes. While true pure-play AI drug discovery companies are relatively rare in public equity markets, HTEC captures targeted exposure to this space. For example, Insilico Medicine (3696), a pioneer in generative AI for drug design, was added to the index soon after its public listing.

More broadly, artificial intelligence has become an essential tool across drug discovery and clinical development. Rather than selecting companies simply because they claim to use AI, HTEC leans on its proprietary Theme Score framework. This process scores companies on technological leadership and investments, ensuring the index selects firms that actively integrate AI to accelerate clinical pipelines and reduce clinical trial failure rates. 

As a result, HTEC provides exposure to both specialized AI drug discovery pioneers and established biopharma leaders utilizing cutting-edge clinical AI tools.

Where Does Healthcare Robotics Stand Today? Where Do You See It Going in the Coming Years? 
Robotics is already heavily deployed across the medical field today. Advanced systems from companies like Intuitive Surgical (ISRG), Globus Medical (GMED), and Stryker (SYK) are widely used for minimally invasive surgeries, orthopedics, and diagnostics. Beyond the operating room, robotics and automation are actively used in pharmacy dispensing, high-throughput lab processing, and hospital logistics.

We project continued, rapid acceleration in healthcare robotics over the next decade. Just as the U.S. manufacturing sector faces structural labor constraints, the healthcare sector is dealing with a compounding shortage of skilled healthcare professionals paired with an aging population that demands more care. Robotics will be heavily relied upon to bridge this gap, driving adoption further into elder care, precision medicine, and telemedicine.

Because we see a massive long-term growth trajectory in this space, the HTEC Index tracks this evolution through targeted exposure across our proprietary subsectors: healthcare robotics, diagnostics, and process automation.

Continuing the Conversation 
Investor interest in healthcare technology is clearly trending upward, and the questions landing on our desks reflect a deepening curiosity about where medical innovation is headed next. This collection highlights several of the most frequent and compelling questions we have received recently, but it is far from a complete list. Medical technology moves quickly, and we are always eager to dive deeper into our Theme Score framework or answer specific inquiries not covered here.

Related Research
Why Moderna’s Cancer Vaccine Matters to Investors

3 Companies Redefining Healthcare Innovation

Healthcare Exposure Focused on Big Pharma? You’re Missing Out

For more news, information, and strategy, visit the Disruptive Technology Content Hub and subscribe to our weekly insights on healthcare technology, AI, and robotics, delivered straight to your inbox.

HTEC is the underlying index for the Robo Global Healthcare Technology & Innovation ETF (HTEC) and the L&G Healthcare Technology & Innovation UCITS ETF (DOCT.LN). 

VettaFi is the index provider for HTEC ETF and DOCT.LN, for which it receives an index licensing fee. However, HTEC ETF and DOCT.LN are not issued, sponsored, endorsed, or sold by VettaFi. VettaFi and its affiliates have no obligation or liability in connection with the issuance, administration, marketing, or trading of  HTEC ETF and DOCT.LN.

Engineers Gate Manager LP decreased its stake in Stryker Corporation (NYSE:SYK – Free Report) by 96.1% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,117 shares of the medical technology company’s stock after selling 27,714 shares during the quarter. Engineers Gate Manager LP’s holdings in Stryker were worth $352,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the stock. Cidel Asset Management Inc. raised its position in Stryker by 6.9% in the 2nd quarter. Cidel Asset Management Inc. now owns 2,080 shares of the medical technology company’s stock valued at $655,000 after purchasing an additional 135 shares during the last quarter. Plimoth Trust Co. LLC increased its stake in shares of Stryker by 1.6% in the second quarter. Plimoth Trust Co. LLC now owns 10,547 shares of the medical technology company’s stock valued at $3,321,000 after buying an additional 171 shares in the last quarter. Capital Analysts LLC increased its stake in shares of Stryker by 6.1% in the second quarter. Capital Analysts LLC now owns 1,469 shares of the medical technology company’s stock valued at $462,000 after buying an additional 85 shares in the last quarter. Pinnacle Wealth Management Advisory Group LLC raised its holdings in shares of Stryker by 3.2% in the second quarter. Pinnacle Wealth Management Advisory Group LLC now owns 1,497 shares of the medical technology company’s stock valued at $471,000 after buying an additional 46 shares during the last quarter. Finally, Community Bank N.A. lifted its position in Stryker by 7.1% during the 2nd quarter. Community Bank N.A. now owns 7,551 shares of the medical technology company’s stock worth $2,377,000 after buying an additional 502 shares in the last quarter. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Stryker Price Performance Shares of SYK stock opened at $272.11 on Friday. The firm has a market capitalization of $104.37 billion, a price-to-earnings ratio of 28.20, a price-to-earnings-growth ratio of 1.70 and a beta of 0.76. The company has a quick ratio of 1.33, a current ratio of 2.16 and a debt-to-equity ratio of 0.59. The firm has a fifty day moving average of $315.01 and a 200-day moving average of $319.18. Stryker Corporation has a 12-month low of $267.00 and a 12-month high of $392.55.

Stryker (NYSE:SYK – Get Free Report) last issued its quarterly earnings data on Thursday, July 30th. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.49 by $0.20. The business had revenue of $6.59 billion during the quarter, compared to analyst estimates of $6.58 billion. Stryker had a return on equity of 23.63% and a net margin of 14.43%.Stryker’s quarterly revenue was up 9.4% compared to the same quarter last year. During the same period in the previous year, the firm earned $3.13 EPS. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. On average, equities research analysts forecast that Stryker Corporation will post 14.98 earnings per share for the current year. Stryker Dividend Announcement The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be issued a dividend of $0.88 per share. The ex-dividend date is Wednesday, September 30th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.3%. Stryker’s dividend payout ratio (DPR) is presently 36.48%.

Analyst Ratings Changes Several research firms have weighed in on SYK. Leerink Partners lowered their price objective on shares of Stryker from $410.00 to $407.00 and set an “outperform” rating for the company in a research report on Friday, June 5th. Canaccord Genuity Group reduced their target price on shares of Stryker from $400.00 to $385.00 and set a “buy” rating on the stock in a research report on Friday, September 18th. Raymond James Financial set a $370.00 price target on shares of Stryker in a research note on Friday, July 31st. TD Cowen lowered their price target on shares of Stryker from $355.00 to $298.00 and set a “hold” rating for the company in a report on Tuesday. Finally, BMO Capital Markets restated an “outperform” rating and issued a $317.00 price objective on shares of Stryker in a research report on Wednesday, September 9th. Eighteen equities research analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. According to MarketBeat.com, Stryker has a consensus rating of “Moderate Buy” and a consensus price target of $374.42.

Check Out Our Latest Report on SYK

Insider Buying and Selling In other news, Director Ronda E. Stryker sold 300,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $335.90, for a total transaction of $100,770,000.00. Following the completion of the transaction, the director directly owned 2,301,375 shares of the company’s stock, valued at $773,031,862.50. This trade represents a 11.53% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Debra King sold 826 shares of Stryker stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $336.30, for a total transaction of $277,783.80. Following the completion of the sale, the insider owned 6,210 shares in the company, valued at $2,088,423. The trade was a 11.74% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 351,267 shares of company stock worth $118,197,701. 4.60% of the stock is owned by corporate insiders.

Stryker Profile (Free Report)

Stryker Corporation is a global medical technology company headquartered in Portage, Michigan. The company develops and manufactures products used by hospitals, physicians and other healthcare providers across a range of medical specialties.

Stryker’s principal businesses include orthopaedics, medical and surgical equipment, and neurovascular products. Its offerings include joint replacement and trauma implants, spinal devices, surgical instruments, operating-room equipment, endoscopy systems, surgical navigation technologies, emergency-care products and devices used to treat neurovascular conditions such as stroke.

Founded in 1941 by Dr.

Read More Five stocks we like better than Stryker Costco Ends Its Fiscal Year on a High Note, Eyes Big Expansion Cracker Barrel Stock Is Rallying Again, But the Turnaround Still Has a Traffic Problem Oracle’s Force Majeure Notice Exposes a Bigger Problem for the AI Build-Out Oil May Be Stronger Than It Looks—And Diamondback Is on Sale

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.

, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Stryker Corp. ("Stryker" or the "Company") (NYSE: SYK). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

The investigation concerns whether Stryker and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On September 8, 2026, Stryker's CEO disclosed at the Wells Fargo Healthcare Conference that a manufacturing problem affecting inventory supply in its peripheral vascular business, which management had previously indicated was expected to resolve during the third quarter of 2026, in fact remained unresolved and was now expected to persist into the fourth quarter. 

On this news, Stryker's stock price fell $26.70 per share, or 8.81%, to close at $276.43 per share on September 8, 2026.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980

SOURCE Pomerantz LLP

Key Takeaways Intuitive Surgical posted 16% procedure growth, led by strong Ion and da Vinci performance in Q2.Stryker's organic sales rebounded to 9% as Mako installations hit records and utilization increased.ISRG's digital ecosystem and international expansion add growth levers despite U.S. and China challenges. Intuitive Surgical (ISRG - Free Report) and Stryker (SYK - Free Report) offer two distinct paths to robotic-assisted surgery. ISRG is building a focused ecosystem around da Vinci, SP and Ion, while Stryker combines Mako robotics with a broad MedTech portfolio spanning orthopedics, surgical technologies, endoscopy and medical products.

ISRG has gained 7.7% over the past month versus a 16.1% decline for SYK. For the rest of 2026, Intuitive Surgical’s faster procedure growth and expanding digital roadmap contrast with Stryker’s recovery-driven and diversified growth opportunity. The Zacks Medical sector was down 2.9% in the same time period, while the S&P 500 Index gained 1.5%.

One-Month Price Performance

Image Source: Zacks Investment Research

Case for ISRGIntuitive Surgical’s operational execution in the second quarter reinforced its robotics thesis. Total procedures grew 17% in the first quarter, followed by 16% growth in the second quarter. The second-quarter improvement was driven by 15% growth in da Vinci and 36% in Ion.

Revenues were up 19% to $2.89 billion in the second quarter. Da Vinci placements reached 468, including 246 da Vinci 5 systems, while SP procedures jumped 61%. Recurring revenues represented 85% of total revenues. Its technology moat is also expanding as da Vinci 5 captures higher-fidelity surgical data, while My Intuitive+ includes AI-driven case insights.

International expansion adds another growth lever. Da Vinci procedures rose 20% outside the United States, while benign procedures in international markets accelerated 37%. Ion procedures reached 48,000 in the second quarter and exceeded 400,000 cumulatively. Key challenges include softer U.S. growth in deferrable procedures, GLP-1 pressure on bariatrics, China’s competitive and pricing environment, and higher R&D and input costs.

ISRG Sales & EPS Growth Estimates

Image Source: Zacks Investment Research

Case for SYKStryker’s second-quarter results showed a meaningful recovery from its first-quarter cybersecurity disruption. Organic sales increased 9% versus 2.4% in the first quarter, with high-single-digit growth in MedSurg and Neurotechnology and Orthopedics. Mako installations reached a record second-quarter level in both the United States and internationally, while utilization increased.

Mako now spans hip, knee, spine and shoulder procedures, with more than 2.5 million procedures completed globally and systems placed in 47 countries. The U.S. launch of Mako RPS further expands the robotics offering.

SYK’s diversified model provides additional growth levers. The second-quarter growth was driven by strong Endoscopy, Medical, Instruments and Trauma and Extremities performance, while connected OR and Smart Care businesses, including Vocera and care.ai, broaden technology exposure.

The AVS acquisition expands peripheral vascular and cardiovascular opportunities. Management expects a strong second half, supported by capital demand, elevated backlog and production recovery. However, operational performance can be hurt by the peripheral vascular supply disruption and continued execution following the cyber incident.

SYK Sales & EPS Growth Estimates

Image Source: Zacks Investment Research

Valuation — ISRG vs SYKAt 34.54X F12M P/E, ISRG trades above the Zacks Medical sector’s 21X P/E, reflecting its growth premium. However, it remains below the five-year median of 67.72X, meaning the current multiple is not elevated versus that historical benchmark.

SYK trades at 16.95X F12M P/E, below the sector multiple and its five-year median of 25.93X. The discount provides valuation support as recovery and product launches progress through 2026.

5-year P/E F12M Chart for ISRG vs SYK and Medical Sector

Image Source: Zacks Investment Research

ConclusionStryker offers a diversified MedTech exposure, with improving capital-product momentum and continued expansion of its Mako franchise. Intuitive Surgical, however, presents the more concentrated growth story. Its 16% procedure growth, 20% international da Vinci growth, 61% SP growth and 36% Ion growth during the second quarter demonstrate stronger operating momentum, while its data-driven digital ecosystem creates a pathway toward AI-enabled differentiation. Despite its sector premium, ISRG’s robotics leadership, recurring revenues and expanding clinical applications make it the more attractive bet currently. Intuitive Surgical carries a Zacks Rank #2 (Buy) at present, while Stryker has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Stryker Corp. (“Stryker” or the “Company”) (NYSE: SYK).  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

The investigation concerns whether Stryker and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On September 8, 2026, Stryker’s CEO disclosed at the Wells Fargo Healthcare Conference that a manufacturing problem affecting inventory supply in its peripheral vascular business, which management had previously indicated was expected to resolve during the third quarter of 2026, in fact remained unresolved and was now expected to persist into the fourth quarter. 

On this news, Stryker’s stock price fell $26.70 per share, or 8.81%, to close at $276.43 per share on September 8, 2026.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes. 

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980 

Key Takeaways Stryker launched Prophecy for Incompass and Hoffmann LRF smartHEX at the 2026 AOFAS meeting.Prophecy adds patient-specific planning, 3D visualization and two fixation options for ankle surgery.smartHEX combines new frame components, mobile patient guidance and updated planning software. Stryker (SYK - Free Report) recently announced the expansion of its Foot & Ankle portfolio with the launch of Prophecy Surgical Planning for the Incompass Total Ankle System and the introduction of Hoffmann LRF smartHEX at the 2026 American Orthopedic Foot & Ankle Society (AOFAS) Annual Meeting. The new additions are designed to advance patient-specific surgical planning, implant flexibility and connected care across ankle replacement and limb reconstruction procedures.

Management highlighted that strong customer adoption and positive feedback for Prophecy have encouraged Stryker to expand the platform to the Incompass Total Ankle System. By combining patient-specific surgical planning with its latest total ankle technology, Stryker aims to help surgeons make more informed decisions before surgery. Management also noted AOFAS as an opportunity to showcase the company’s decades of foot and ankle expertise, customer insights and data. The addition of Prophecy Surgical Planning for Incompass and Hoffmann LRF smartHEX further connects planning, implants and reconstruction technologies, providing surgeons with greater flexibility across foot and ankle care.

Likely Trend of SYK Stock Following the NewsFollowing the announcement, SYK stock gained 1.2% at yesterday’s close. Year to date, shares of the company have fallen 18.9% compared with the industry’s 21.2% decline. However, the S&P 500 has risen 10.1% in the same timeframe.

Stryker could see increased demand for its Foot & Ankle offerings by expanding its technology-enabled solutions across total ankle replacement and complex limb reconstruction. Prophecy’s availability with Incompass could support adoption by connecting patient-specific planning with implant selection, while Hoffmann LRF smartHEX broadens the company’s connected limb reconstruction capabilities. Together, the launches may improve cross-selling opportunities, increase surgeon engagement and support portfolio growth across multiple orthopedic procedures.

SYK currently has a market capitalization of $107.98 billion.

Image Source: Zacks Investment Research

More on Prophecy and Hoffmann LRF smartHEXProphecy Surgical Planning has supported more than 100,000 ankle cases over the past 14 years. Its integration with the Incompass Total Ankle System provides surgeons with patient-specific surgical planning, enhanced 3D visualization and both resect-through and pin-through fixation options within a connected platform. The Incompass system itself was developed using insights from Prophecy and SOMA, incorporating real-world anatomy and surgical planning into implant design.

Hoffmann LRF smartHEX expands Stryker’s limb reconstruction portfolio with new rings, struts and frame components, along with a mobile application and updated planning software. The platform is designed to support complex deformity correction by connecting patient guidance, surgeon planning and correction capabilities throughout treatment.

Through its mobile application, smartHEX enables patients to stay connected with their surgeon-prescribed correction plan, while the updated planning software and expanded frame options provide greater versatility for limb reconstruction procedures. Together, the two additions reflect Stryker’s efforts to connect digital planning, implants and reconstruction technologies across Foot & Ankle care.

Industry Prospects Favoring the MarketGoing by the data provided by Precedence Research, the global foot and ankle devices market is estimated to reach $5.8 billion in 2026 and is projected to witness a CAGR of 6.8% through 2035.

Factors such as the rising prevalence of musculoskeletal disorders, increasing incidence of weakened bones and reduced bone density, the increasing number of sports injuries and accidents, surging demand for cosmetic foot surgery and continued advancements in total ankle replacement technologies are supporting market growth.

Other NewsStryker recently announced the successful completion of the first surgical procedure using SportSuite Vision on Apple Vision Pro at Duke Health. FDA-authorized in July, SportSuite Vision is the first application cleared for intraoperative use with Apple Vision Pro. The technology brings digital content, including arthroscopic images, HipCheck, HipMap and CT imaging, into surgeons’ visual fields, reducing reliance on multiple OR monitors and supporting a more streamlined, ergonomic surgical workflow.

SYK’s Zacks Rank & Key PicksStryker currently carries a Zacks Rank #3 (Hold).

Some better-ranked stocks from the broader medical space are Veracyte (VCYT - Free Report) , Inspire Medical Systems (INSP - Free Report) and Globus Medical (GMED - Free Report) .

Veracyte, currently sporting a Zacks Rank #1 (Strong Buy), reported second-quarter 2026 adjusted earnings per share (EPS) of 54 cents, which surpassed the Zacks Consensus Estimate by 25.6%. Revenues of $150.3 million beat the Zacks Consensus Estimate by 4.1%. You can see the complete list of today’s Zacks #1 Rank stocks here.

VCYT has an estimated earnings growth rate of 8.4% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 41.8%.

Inspire Medical, currently sporting a Zacks Rank #1, reported second-quarter 2026 adjusted EPS of 14 cents, which beat the Zacks Consensus Estimate by 163.6%. Revenues of $200.6 million surpassed the Zacks Consensus Estimate by 2.9%.

INSP has an estimated long-term earnings growth rate of 10.6%. INSP’s earnings surpassed estimates in the trailing four quarters, the average surprise being 195.9%.

Globus Medical, currently carrying a Zacks Rank #2 (Buy), reported a second-quarter 2026 adjusted EPS of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%.

GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.

Investors looking for stocks in the Medical - Products sector might want to consider either GE HealthCare Technologies (GEHC) or Stryker (SYK). But which of these two stocks is more attractive to value investors?

9.67K Followers

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Stryker Corporation (“Stryker” or the “Company”) (NYSE: SYK) investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN STRYKER CORPORATION (SYK), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. Contact the Law Offices of Howard G. Smith to discuss your legal rights by email.

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Stryker Corporation (“Stryker” or the “Company”) (NYSE: SYK) investors concerning the Company's possible violations of the federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON STRYKER CORPORATION (SYK), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. What Happened? On Ju.

Stryker Corporation (SYK) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

8.9.2026 22:09

Zámořské akciové trhy zakončily dnešní obchodování v záporném teritoriu. Index Dow Jones klesl o 1,18 % na 52 786,28 bodu, S&P 500 si odepsal 0,58 % a technologický Nasdaq Composite ztratil 0,32 %. Hlavním důvodem poklesu byl růst cen ropy způsobený geopolitickým napětím na Blízkém východě, který opět rozproudil obavy z vyšší inflace a možného zvýšení úrokových sazeb ze strany centrální banky.

V rámci indexu S&P 500 se nejvíce dařilo energetickému sektoru s růstem o 1 %, utilitám se ziskem 0,9 % a realitám, které přidaly 0 %. Naopak nejvýraznější propad zaznamenala zdravotní péče se ztrátou 2,6 %, finanční sektor klesající o 1,4 % a základní materiály nižší o 0,9 %. Z jednotlivých akcií výrazně posílily společnosti Lumentum Holdings (LITE) o 11 %, Intel Corp (INTC) o 9,1 %, Corning (GLW) o 7,6 %, Coherent Corp (COHR) o 7,1 % a Hewlett Packard Enterprise (HPE) o 7,8 %. Naopak nejvýrazněji propadly akcie společností Amgen (AMGN) o 10 %, Howmet Aerospace (HWM) o 11 %, Stryker Corp (SYK) o 8,8 %, Expedia Group (EXPE) o 7,9 % a GoDaddy (GDDY) o 8,3 %.

Na dluhopisovém trhu rostly výnosy krátkodobých cenných papírů a výnos desetiletého amerického vládního dluhopisu mírně stoupl na 4,79 %. Měnový trh zůstal bez výraznějších změn, euro stagnovalo na úrovni 1,1623 USD a kurz japonského jenu se pohyboval kolem 154,30 JPY za dolar. Komodity zaznamenaly smíšený vývoj, když lehká ropa WTI posílila o 1 % na 92,43 USD za barel, zatímco spotové zlato mírně odepsalo 0,3 % na 4 392,74 USD za trojskou unci.

Index Dow Jones -1,18 % na 52786,28 b.
S&P 500 -0,58 % na 7673,51 b.
Nasdaq Composite -0,32 % na 26421,41 b.

Index S&P 500 -0,58 % na 7673,51 b. Nejsilnější sektory S&P Změna Nejslabší sektory S&P Změna Energie +1 % Zdravotní péče -2,6 % Utility +0,9 % Finanční sektor -1,4 % Reality +0 % Základní materiály -0,9 % Nejsilnější akcie S&P Změna Nejslabší akcie S&P Změna Lumentum Holdings (LITE) +11 % Howmet Aerospace (HWM) -11 % Intel Corp (INTC) +9,1 % Amgen (AMGN) -10 % Hewlett Packard Enterprise (HPE) +7,8 % Stryker Corp (SYK) -8,8 % Corning (GLW) +7,6 % GoDaddy (GDDY) -8,3 % Coherent Corp (COHR) +7,1 % Expedia Group (EXPE) -7,9 %
Daniel Marván, Fio banka, a.s.